Corvus Pharmaceuticals (CRVS) Long-Term Investments (2020 - 2026)

Corvus Pharmaceuticals' Long-Term Investments history runs 7 years deep, the most recent figure standing at $10.5 million for Q1 2026.

• On a quarterly basis, Long-Term Investments fell 12.95% year-over-year to $10.5 million in Q1 2026; TTM through Mar 2026 was $10.5 million, a 12.95% decrease from a year earlier, with the FY2025 full-year figure at $11.0 million, down 12.35% from the prior year.
• Long-Term Investments retreated to $10.5 million in Q1 2026 per CRVS's latest filing, from $11.0 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $33.4 million in Q1 2022 and bottomed at $10.5 million in Q1 2026.
• The 5-year median for Long-Term Investments is $16.1 million (2024), against an average of $17.6 million.
• Across the five-year window, Long-Term Investments decreased 10.11% in 2022 and slumped 40.3% in 2023, its largest moves.
• Year by year, Long-Term Investments stood at $21.9 million in 2022, then declined by 26.3% to $16.1 million in 2023, then retreated by 22.22% to $12.5 million in 2024, then fell by 12.35% to $11.0 million in 2025, then retreated by 4.5% to $10.5 million in 2026.
• Per Business Quant, the three latest CRVS Long-Term Investments figures stand at $10.5 million (Q1 2026), $11.0 million (Q4 2025), and $11.5 million (Q3 2025).